Abstract
Oncology clinical trials are often complex leading to years of research and generation of vast amounts of data. Statistical graphics play an invaluable role in transforming these multifaceted data into crisp and simplified visuals that assist researchers to quickly and accurately study the results, detect data trends and patterns, and suggest hypotheses. In other words, “Excellence in statistical graphics consists of complex ideas communicated with clarity, precision, and efficiency.” The focus of this chapter is to provide a sampling of useful statistical graphics routinely used in clinical oncology research and their utility in communicating information clearly and more efficiently than solely reviewing tables of numerical output. The graphics presented are commonly used during trial design planning, interim analyses, and final analyses of clinical efficacy data.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
American Cancer Society (2012) Cancer facts & figures 2012. American Cancer Society, Atlanta
Anand P, Kunnumakkara A et al (2008) Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25(9):2097–2116
Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17:1103–1120
CancerHelp UK (2012) How many different types of cancer are there? http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions/how-many-different-types-of-cancer-are-there. Accessed 01 March 2012
Cappelleri J, Ioannidis J, Lau J (2000) Meta-analysis of therapeutic trials. In: Chow S-C (ed) Encyclopedia of biopharmaceutical statistics. Marcel Dekker, Inc., New York, NY, pp 307–316
CenterWatch (2012) FDA Approved Drugs for Oncology. http://www.centerwatch.com/drug-information/fda-approvals/drug-areas.aspx?AreaID=12. Accessed 10 Apr 2012
Chuang-Stein C, Le V, Chen W (2001) Recent advancements in the analysis and presentation of safety data. Drug Inf J 35:377–397
Cleveland W (1993) Visualizing data. Hobart Press, Summit, NJ
Cox D (1972) Regression models and life-tables (with discussion). J R Stat Soc 34:187–220
Food and Drug Administration (2007) Guidance for industry: Clinical Trial Endpoints for the Approval of cancer drugs and biologics, [WWW] http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (cited 01 September 2012. 10.22), Rockville, MD, U.S. Department of Health and Human Services, Food and Drug Administration
Fox J (2002) An R, S-PLUS Companion to Applied Regression: Cox Proportional-Hazards Regression for Survival Data, Sage Publications, Inc., Thousand Oaks, CA
Jennison C, Turnbull B (2000) Group sequential tests with Applications to Clinical Trials. Chapman and Hall/CRC, Boca Rotan, FL
Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Lee J, Liu D (2008) A predictive probability design for phase II cancer clinical trials. Clin Trials 5(2):93–106
Lin Y, Shih W (2001) Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2(2):203–215
Loprinzi C et al (1994) Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol 12(3):601–607
National Cancer Institute (2012) Defining Cancer. http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer. Accessed 01 March 2012
O’Connell M, Treder B (2009) Overview of Descriptive and Graphical Methods for Time-to-Event Data. In: Design and analysis of clinical trials with time-to-event endpoints. Chapman and Hall/CRC, Boca Rotan, FL, 227–239
O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase I clinical studies in cancer. Biometrics 46:33–48
O’Quigley J, Reiner E (1998) A stopping rule for the continual reassessment method. Biometrika 85:741–748
Parmar M, Machin D (1995) Survival analysis: a practical approach. Wiley, New York
Reiner E, Paoletti X, O’Quigley J (1999) Operating characteristics of the standard phase I clinical trial design. Comput Stat Data Anal 30:303–315
Reuters (2012) Cancer drug sales could hit $80 billion by 2011: IMS. http://www.reuters.com/article/2008/05/15/us-cancer-forecast-idUSN1453543620080515. Accessed 10 Apr 2012
Schlesselman J, Reis I (2006) Phase II clinical trials in oncology: strengths and limitations of two-stage designs. Cancer Invest 24:404–412
Seeking Alpha (2012) U.S. Prescription Drug Sales Grow Slowly; Hydrocodone Most Prescribed. http://seekingalpha.com/article/128003-u-s-prescription-drug-sales-grow-slowly-hydrocodone-most-prescribed. Accessed 10 Apr 2012
Simon R (1989) Optimal two-stage designs for Phase II clinical trials. Control Clin Trials 10:1–10
Simon R et al (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:15
Storer B (1989) Design and analysis of phase I clinical trials. Biometrics 45:925–937
Therneau T (2012) <therneau.terry@mayo.edu> Survival analysis, including penalised likelihood. R package version 2.36-12. http://CRAN.R-project.org/package=survival, Accessed September 1, 2012
Tighiouart M, Rogatko A, Babb J (2005) Flexible Bayesian methods for cancer phase I clinical trials: dose escalation with overdose control. Stat Med 24:2183–2196
Tufte E (1983) The visual display of quantitative information. Graphics Press, Cheshire, CT
Tufts Center for the Study of Drug Development (2006) Average Cost to Develop a New Biotechnology Product Is $1.2 Billion, According to the Tufts Center for the Study of Drug Development, 9 November 2006. http://csdd.tufts.edu/NewsEvents/NewsArticle.asp?newsid=69. Accessed 18 Dec 2006
Whitehead J (1997) The design and analysis of sequential clinical trials (revised 2nd edition). Wiley, New York
Acknowledgments
The author thanks Kara Choquette, Thian Kheoh, Byron McKinney, Sandeep Menon, Michael O’Connell, and Denise Trone for their many insightful comments and recommendations that led to the improvement in the structure, content, and focus of the chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, New York
About this chapter
Cite this chapter
Gilder, K. (2012). Statistical Graphics in Clinical Oncology. In: Krause, A., O'Connell, M. (eds) A Picture is Worth a Thousand Tables. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-5329-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5329-1_9
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-5328-4
Online ISBN: 978-1-4614-5329-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)